# Arthurian Life Sciences

> Arthurian Life Sciences is a VC fund backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 5
- Last investment: Jun 2016
- Lead investor: 60%
- Fund size: $160M
- Last fund: Mar 2012
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/company/arthurian-life-science
- Website: http://arthurianlifesciences.co.uk/

Arthurian Life Sciences is a VC fund in London focused on Health Care and Biotechnology. Arthurian Life Sciences Ltd was established by Europe’s leading biotech entrepreneur Professor Sir Chris Evans OBE to act as General Partner of the Wales Life Sciences Investment Fund, a £100 million fund and key part of the Welsh Government’s Life Sciences initiative, as outlined by the Minister for Business, Enterprise, Technology and ScienceEdwina Hart at the BioWales Conference in 2012.The Fund had its first closing with £50 million on 28th February 2013.

## Contacts

5 contacts available for Arthurian Life Sciences. Shizune tracks 3 team members at Arthurian Life Sciences. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/arthurian-life?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 80% |
| Biotechnology | 3 | 60% |
| Medical | 2 | 40% |
| Therapeutics | 2 | 40% |
| Medical Device | 2 | 40% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 2 | 40% |
| Seed | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 80% |
| Switzerland | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brenig Preest | Investment Director | 0 | — |
| Christopher Thomas Evans | Chairman | 1 | — |
| Owen Smith | Investment Manager | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Verona Pharma | Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. | $65.6M | Post-IPO Equity | Jun 20, 2016 | http://www.veronapharma.com |
| Rutherford Health | Rutherford Health is at the vanguard of advancing cancer care, building a series of oncology centres known as the Rutherford Cancer Centres.Offering world-class proton beam therapy, along with diagnostics, chemotherapy, radiotherapy, and holistic therapy, treatment at the centres will be available to medically-insured private patients,self-paying patients and patients referred by the NHS. |  | Seed | Jan 01, 2016 | https://www.rutherfordhealth.com/ |
| Apitope | Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of productcandidates developed with its proprietary platform technology. | $13.5M | Series B | Sep 29, 2015 | http://apitope.com/ |
| CeQur | CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $100M | Series C | Sep 01, 2015 | http://www.cequrcorp.com |
| Sphere Medical Holding | Sphere Medical Holding PLC develops, manufactures, and commercializes monitoring products for critical care environments in the United Kingdom and internationally. The company offers microanalyser platforms that are used to measure clinical analytes, including pH, glucose, potassium, sodium, calcium, oxygen, Hct, and carbon dioxide. Its productsinclude analyzers for intensive care units and operating rooms; and cardiopulmonary bypass monitors, monitoring catheters, and intravenous anaesthetic analyzers. The company's products also include systems for the intermittent analysis and continuous monitoring of blood and other fluids; and sensors for catheters or other measurement probes. Its products provide healthcare professionals the information to manage therapy and optimize patient outcomes. Sphere Medical Holding PLC was formerly known as Sphere Medical Holding Ltd. and changed its name in November 2006. The company was founded in 2002 and is based in Cambridge, the United Kingdom. | $19.4M | Post-IPO Equity | Apr 21, 2015 | http://www.spheremedical.com |

5 of 5 investments shown.

## Co-investors
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Arix Bioscience](https://shizune.co/investors/profile/arix-bioscience) — VC Fund, 1 deal together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 1 deal together
- [Edmond de Rothschild Private Equity](https://shizune.co/investors/profile/edmond-de-rothschild-private-equity) — VC Fund, 1 deal together
- [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Arthurian Life Sciences invest in?

Arthurian Life Sciences invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity and Seed stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Arthurian Life Sciences?

Public channels for Arthurian Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Arthurian Life Sciences?

The team at Arthurian Life Sciences includes Brenig Preest (Investment Director), Christopher Thomas Evans (Chairman) and Owen Smith (Investment Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co